- RESEARCH HIGHLIGHT
Improving leukaemia treatment with bispecific antibodies
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature Reviews Drug Discovery 22, 538 (2023)
doi: https://doi.org/10.1038/d41573-023-00091-z
References
Moles, E. et al. Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia. Sci. Transl Med. 15, eabm1262 (2023)